Considering that in the early stages of Alzheimer’s disease the amount of “normal” extracellular tau is probably higher overall, the inability to discriminate between PHF-tau and “normal” tau could result in losing therapeutic effect. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.